Trust Policy	Worcestershire Acute Hospitals NHS Trust

Guideline for the Use of Negative Pressure Wound Therapy (NPWT)

Department / Service:	Tissue Viability
Originator:	Claire Hughes Lead Nurse Tissue Viability
Accountable Director:	Chief Nurse
Approved by:	Clinical Governance Group
Date of approval:	2nd March 2021
Review date **This is the most current document and should be used until a revised version is available**	2nd September 2024
Target Organisation(s)	Worcestershire Acute Hospitals NHS Trust
Target Departments	
Target staff categories	

Policy Overview:

This policy provides guidance for staff at Worcester Acute Hospitals NHS Trust about the requirements and processes for commencement and on-going management of Negative Pressure Wound Therapy (NPWT)

Key areas:

- Defined duties and responsibilities for staff
- Defined processes for commencing NPWT and its on-going management
- Defined identification of potential complications and when to discontinue NPWT
- Defined process for discharging patients with NPWT

Key amendments to this document

Date	Amendment	Approved By:
August 2017	Document extended for 6 months as per TMC paper	TMC
December 2017	Sentence added in at the request of the Coroner	
December 2017	Document extended for 3 months as per TLG recommendation	TLG
March 2018	Document extended for 3 months as approved by TLG	TLG
June 2018	Document extended for 3 months as per TLG recommendation	TLG
April 2019	Document extended for 6 months whilst review process is undertaken	Lisa Hill
March 2020	Document extended for 3 months whilst review is completed	Lisa Hill
June 2020	Document extended for 6 months during COVID-19 period	
January 2021	Policy Reviewed and WAHT-NUR-082 archived as same document.	Lisa Hill
February 2021	Document extended as per Trust agreement 11.02.2021	
March 2021	Document approved for 3 years	CGG
19/03/2024	Document extended for six months	Claire Hughes

Contents page:

Appendices

Appendix 1

Supporting Documents

Supporting Document 1	Equality Impact Assessment
Supporting Document 2	Financial Risk Assessment

1. Introduction

Negative Pressure Wound Therapy (NPWT) also known as Topical Negative Pressure (TNP) or Vacuum Assisted Closure (V.A.C®) is a medical device to obtain a vacuum within the wound via foam or gauze interface to promote wound healing. Both the suction effect and the mechanic forces generated in the wound can positively influence wound healing. NPWT also assists in the removal of excess exudate thereby reducing local oedema. As such, NPWT can improve wound healing and health related quality of life.

Worcester Acute NHS Trust currently uses Vacuum Assisted Closure (V.A.C. ®), V.A.C VERAFLO™ ABThera™ to provide NPWT.

NPWT has been found to facilitate healing in acute, chronic, closed incisional, closed skin graft and open abdominal wounds.

Due to its specific mode of action practitioners require training and must follow the recommended guidelines in order to reduce risk and achieve the best outcomes for the patient. In addition to a wound assessment, practitioners must also assess the patient's suitability to be able to manage the device.

A wealth of clinical experience suggests that NPWT is a clinically- and cost effective treatment that can be used to provide maximum therapeutic benefits to the patient with complex wounds (Wounds UK, 2008).

2. Scope of this document

Provide support and guidance to staff in selecting and accessing NPWT as a safe, appropriate wound care therapy option for patients

- Reduce risks in implementation of NPWT, ensuring patient safety
- Ensure accurate documentation on ongoing management of NPWT
- Ensure early identification of patients who may require NPWT on discharge so the appropriate referrals can be made by the clinical teams.

This policy applies to all clinical areas in Worcester Acute Trust where staff are responsible for the implementation and on-going management of patients with NPWT.

It is the responsibility of staff to ensure they are trained and assessed as competent before undertaking NPWT. (Appendix10)

3. Definitions

NPWT – Negative Pressure Wound Therapy

V.A.C® - Vacuum Assisted Closure

V.A.C. - VERAFLO ™– VAC therapy combining wound instillation with topical solutions

ABThera™ - Open Abdomen NPWT system – **CONSULTANT LEAD THERAPY**

Competent- having the necessary ability, knowledge or skills to complete something successfully

Exudate – the material composed of serum, fibrin and white blood cells that escapes from the blood vessels into superficial lesions or areas of inflammation

Colonisation – the presence of bacteria on a body surface

Malignancy – the state or presence of a malignant tumour, cancer

Necrotic – dead cells or tissues usually in a localised area of the body

Osteomyelitis – inflammation or bone or bone marrow, usually due to infection

Haemostasis – the stopping of blood flow

Fistula – an abnormal or surgically made passage between a hollow or tubular organ and the body surface, or between two hallow or tubular organs

4. Responsibility and Duties

4.1 Medical Staff

Medical staff involved with NPWT must be aware of how NPWT works and what the indications, contraindications and precautions are as well as the possible complications; this will ensure they can make informed decisions on the appropriateness of commencing NPWT.

Medical staff who are competent in NPWT are able to authorise the application of NPWT for a patient.

ABThera™ – is a Consultant Lead Therapy. Medical staff involved must be aware of how ABThera™ works, indications, contraindications and precautions as well as possible complications. They must be aware of its correct application and undergo relevant training for the use of this therapy.

4.2 Matrons, Ward and Department Managers

Registered practitioners have a duty of care, which cannot be delegated. They are responsible for individual patient assessment and implementation and evaluation of the strategies to ensure appropriate use of NPWT therapy outlined in this policy.

Ward/department managers are responsible for ensuring that staff of all disciplines within their clinical area adheres to Worcester Acute NHS trust NPWT policy.

Ward managers to ensure they have adequate numbers of staff who have completed NPWT training and are signed off as competent. This may also include ward based training on the management of NPWT devices for those managing patients with NPWT but not undertaking assessments or dressing changes.

Ward / Department managers will ensure that sufficient stock levels of V.A.C® therapy products are available to ensure the “Right V.A.C Dressing is available at the Right Time to ensure the Right treatment management plan”. (Appendix 13, 14)

4.3 Tissue Viability Nurse (TVN)

The TVN will assist ward staff to assess and ensure appropriate management plans in place for the ongoing care of patients with complex wounds requiring NPWT.

Tissue Viability will support the practical application and assessment of competence

TVN will ensure that theoretical knowledge provided by company (3M&KCI) clinical advisors is in line with Trust policy and any evidence based changes will be reflected in policy updates.

4.4 Registered Nurses

Ward/department staff MUST follow Worcester Acute NHS Trust NPWT policy.

Registered nurses have responsibility to ensure that their knowledge and skills are up to date in order to maintain and develop their competence.

A full, comprehensive wound assessment must be completed and documented on the relevant NPWT care plan; this must include a minimum of weekly wound measurements. Photography of the wound should be taken prior and at regular intervals during NPWT treatment. If any issues are identified with the therapy this must be escalated to the Consultant team or TVN and actions implemented in line with policy and those actions documented in the patient’s medical notes.

5 Policy:

NPWT is a non-invasive active wound healing therapy. Due to its specific mode of action staff require training and competence.

Before NPWT can be commence there must be agreement between the Lead Clinician, patient, registered nurses, including TVN that this therapy is appropriate for the wound and have an agreed treatment aims and objectives.

NPWT comprises of a sealed dressing over a wound, a suction pump and a drainage tube going from inside the dressing or its surface to a canister within the pump unit (Ritchie et al, 2010).

NPWT progresses a wound towards healing by maintaining a moist wound environment, improving micro-vascular blood flow, controlling exudate, stimulating tissue formation and reducing wound size by pulling the wound edges together (Abbots ,2010).

Additionally NPWT can reduce bacterial load, eliminate wound odour and improve quality of life for patients (Stephen-Haynes et al, 2011a & EWMA, 2007).

Indications for NPWT: (Appendix 5)

NPWT should be considered for the management of the following wounds (Wounds UK, 2008):

- Dehisced surgical wounds
- Diabetic/neuropathic ulcers
- Chronic wounds
- Partial/full thickness pressure ulcers (EPUAP, 2009 & NICE, 2005)

Contra-indications for NPWT:

Research has highlighted that NPWT is not suitable for all patients with wounds (EWMA, 2007, Benbow, 2008, Thompson , 2008, & Malahias, 2012) and to ensure the safe, effective and appropriate use of NPWT the following contra – indications and precautions need to be considered:

- Patient non-concordance (Thompson, 2008)
- Malignancy within the wound, known or suspected
- Osteomyelitis, untreated by appropriate antibiotic therapy
- Necrotic tissue, hard eschar
- Exposed blood vessels, nerves, anastomotic sites or organs
- Wounds with fistulas opening into a body cavity
- Wounds where acute or chronic enteric fistulas are present
- Wounds with sharp edges or where bone fragments are present
- Non enteric and unexplored fistula
- Impaired mental capacity (refer to Mental Capacity Act, 2005)
- Patients must be able to carry the NPWT device safely and not be considered a falls risk

- Unsuitable home environment and/or social circumstances
- The gauze contains Polyhexamethylene Biguanide (PHMB) antiseptic, which may present a risk of an adverse reaction to patients who are allergic or have a known hypersensitivity to PHMB. If a patient has a known allergy or hypersensitivity to PHMB, do not use K.C.I's NPWT Gauze dressings.

Precautions:

- Difficult wound haemostasis/active bleeding, ensure that the patients International Normalised Ratio (INR) is within a safe range to consider NPWT (0.8-1.2)
- Patients who have been administered anticoagulants or platelet aggregation inhibitors
- Patients who do not have adequate tissue coverage over vascular structures
- Any exposed bone or tendon needs to be protected with a LINER prior to application of the foam. LINER must be open mesh silicone non-adherent contact layer. If unsure of the need to protect underlying structures proceed with caution and use LINER.

Treatment objective:

To achieve the optimum outcome from NPWT it is important that treatment objectives are determined between the Registered Healthcare Professional and the patient. These same treatment objectives should be reassessed weekly to ensure that NPWT continues to be the most appropriate treatment for the patient (Milne, 2013).

Examples of treatment objectives for patients suitable for NPWT are (Abbots, 2010):

- To improve the patients quality of life
- To manage the amount of exudate
- To promote improvement in the wound bed by improving vascularity
- The production of granulation tissue
- Reduce bacterial bio-burden

Assessment:

To determine whether NPWT is suitable for a patient it is vital that a full holistic assessment is completed, considering nutritional risk, pressure ulcer risk, cognitive ability and mobility. Additionally it is important that the patient's home environment and social circumstances are assessed and considered to be safe for NPWT (Milne, 2013). Mental capacity needs to be considered when assessing a patient for NPWT to ensure safe and effective use of the treatment.

A wound assessment must be completed including size, depth, type of tissue, exudate, presence of infection, condition of surrounding skin and a photograph as per Worcestershire Acute NHS Trust Wound Management policy for a wound to be suitable for NPWT there should be at least 2cm of skin surrounding the wound to enable a seal to be maintained. Additional help may be needed if less than a 2 cm area of intact skin surrounds the wound and the use of Gel Strips should be considered.

- The patient must have a pain assessment completed to ensure that the patient's pain is adequately managed and that they remain comfortable during NPWT, dressing changes and post dressing change.
- Patients with a chronic wound should have a Full Blood Count test and any anaemia treated.
- Where a wound is identified as being delayed in healing a blood glucose test should be taken to assess for diabetes. Additionally good glycaemic control should be attained for patients with diabetes.
- Patients who require NPWT on the lower limbs must have an differential diagnosis including a Doppler ultrasound assessment if the wound is over 2 weeks old and classified as a leg ulcer
- Tissue Viability specialist advice MUST be sought when considering NPWT for paediatric patients.
- Patients need to be educated about how the NPWT system works and what to do if a technical problem occurs. Patients also need to be able to recognise any signs and symptoms of complications and technical problems. (Appendix 11). Registered Healthcare Professionals need to ensure that patients are aware of what to do and who to contact in the event of a problem occurring during NPWT. If there is any concern regarding a patient managing in the event of a problem occurring then the patient should be deemed as unsuitable for NPWT and alternative treatments should be sought. Trust Contract Provider has a 24hr free helpline clinical helpline 08009808880.
- The patient must be given information about NPWT to allow them to make informed consent. Patients must understand the rationale for treatment, the interventions required to apply and maintain the therapy. Registered Healthcare Professionals must obtain verbal consent from the patient and this must be documented in the patient's notes.

How NPWT works:

Negative pressure wound therapy (NPWT) is a non-invasive therapy by which negative pressure is delivered uniformly to a wound which in turn:

- Directly stimulates cell proliferation
- Increases local blood perfusion
- Promotes granulation tissue formation
- Reduces localised oedema
- Removes wound exudate
- Pulls wound edges together
- Provides a closed moist wound healing environment

V.A.C® therapy and V.A.C. VERAFLO ™ therapy (3M&KCI) (Appendix8, 9)

V.A.C® therapy is an integrated system incorporating either a polyurethane or polyvinyl alcohol foam dressing that acts as an interface between the wound surface and the vacuum source. The foam dressing is covered is covered using a transparent, semi-occlusive adhesive drape; a

SensaT.R.A.C pad (with integrated tubing) is then applied and connected to the ActiV.A.C® therapy unit (Appendix 9).

There are two types of foam dressings available to use with the V.A.C® Therapy.

- The Granufoam is a black, polyurethane (PU) foam dressing with reticulated (open) pores to help evenly distribute negative pressure across the wound bed, assisting in tissue granulation formation in wounds and aiding wound contraction. It is hydrophobic (or moisture repelling), which enhances exudate removal (Banwell, 2007). There is also an antimicrobial option, which includes 10% silver for the use of infected wounds.
- The white polyvinyl alcohol foam is dense, open-pore foam with a higher tensile strength for use in tunnels and undermining. It is hydrophilic (or moisture retaining) and is packaged pre-moistened with sterile water. Its characteristics help to reduce the likelihood of adherence to the wound bed. V.A.C. ® White Foam Dressing may be used to assist in minimizing discomfort or in situations where over granulation responses are likely (Banwell, 2007).
- There is a gauze antimicrobial roll dressing that can be used with the NPWT as an alternative to foam dressings.

V.A.C. **VERAFLO** ™ therapy combines negative pressure wound therapy (NPWT) and wound instillation with topical solutions for wound healing. The therapy system delivers automated cycles of wound cleansing, removal of infectious material and exudate depending on the wound (NICE, 2019)

V.A.C. ® Therapy with InstillationV.A.C. VERAFLO™ Therapy combines the benefits of V.A.C. ® Therapy with automated topical wound solution distribution and removal.

V.A.C. VERAFLO™ Therapy can help:

- Cleanse with the instillation of topical wound cleansers
- Treat with the instillation of topical antimicrobial and antiseptic wound solutions
- Heal the wound and prepare for closure

V.A.C. VERAFLO™ Therapy consists of NPWT coupled with automated, controlled delivery to and removal of topical wound treatment solutions from the wound bed.

V.A.C. VERAFLO CLEANSE CHOICE™ Dressing
Is used in conjunction with V.A.C. ULTA™ Therapy System is ideal to facilitate the removal of thick wound exudate, such as fibrin (wet slough), and other infectious material. (Appendix 8). The unique, 3 layer design can be used for wounds with complex geometries; including explored tunnels or undermining where the distal aspect is not visible. The contact layer with a pattern of 1 cm holes provides mechanical movement at the wound surface, in combination with cyclic delivery and dwell of topical solutions. The 2 cover layers without holes are designed to help capture large wound exudate before they enter into the tubing, they also provide application options for wounds with varying depths. Subject to clinical assessment, may be considering when surgical debridement is not possible or not appropriate.

V.A.C. VERAFLO™ Therapy is also unique in that it uses dressings specifically designed for instillation therapy with NPWT. The dressings are less hydrophobic than the current V.A.C. ® Therapy Dressings and provide improved fluid distribution within, and removal from, the wound bed

The V.A.C.ULTA™ Therapy System is designed to provide therapeutic options that can be customized for different wound care needs. NPWT parameters, such as negative pressure settings, and duration of negative pressure therapy between instillation cycles, can also be customized. With V.A.C. VERAFLO™ Therapy, the user can select the appropriate topical wound solution needed for each wound to be treated (such as normal saline or wound irrigation solutions and cleansers) as well as adjust the instillation fill volume and soak time. There are currently three dressing options to choose from for use with V.A.C. VERAFLO™ Therapy. Each dressing allows clinicians to customize therapy based on the goal of therapy.

NPWT application process: see Dressing Application (Appendix 6)

- Prior to commencement of procedure hands should be thoroughly washed and dried. Following cleansing a protective disposable apron should be worn.
- The surrounding skin should be cleansed at each dressing change only irrigate/cleanse the wound bed if there is specific debris to remove prior to application of NPWT foam.
- Pressure settings applied are dependent on the type of wound, (Appendix 7)
- An odour can occur with some wounds, the Healthcare Professional needs to consider the cause of the odour.
- Canisters should be monitored daily for exudate quantity and type. It is recommended that canisters are replaced when full (an alarm will sound) and at least once a week to control odour.
- It is recommended that dressings are changed every 48 – 72 hours but no less than 2 times per week, based on individual assessment. Infected wounds may need to be changed more frequently.
- The patient should be advised to inform a Healthcare Professional if they experience severe pain or acute bleeding. It is important to inform the patient of any adverse reactions so to ensure that they are prepared for such occurring. The patient must be aware of who to contact in the event of an adverse reaction occurring, buzzer should be near patient at all times.
- Any pain or acute bleeding the pump must be turned off. Contact the Tissue Viability Team, doctor on call or 24 hour helpline on 08009809808880
- The therapy must not be switched off for longer than 30 minutes and a maximum of 4 times in each 24-hour period. If a seal cannot be achieved and maintained the dressing is to be removed and the therapy should be discontinued. The patient should then be re-assessed, an alternative treatment sought and the NPWT device returned to the supplier.
- Full documentation of the therapy should be recorded in the patient's notes.
- It is recognised that waste generated during canister changes should be disposed of as Clinical Waste.

- ***It is important to record and document clearly of the number of pieces used and the foam type (white or black) to ensure no foam is retained within the wound bed on wound assessment chart.***
- ***If the wound is to be dressed using gauze dressing then a gauze dressing that can be used with the NPWT is placed in the wound. A record of the number of pieces used made.***

When to discontinue NPWT:

NPWT should be discontinued after a Registered Healthcare Professional has assessed the wound and concluded that the treatment objective has been achieved (Bondokji et al 2011 & Milne, 2013).

Alternatively, NPWT should be stopped when a patient is assessed by a Registered Healthcare Professional as not being suitable to continue with the treatment.

Considerations for stopping NPWT include:

- At the patient's informed request
- When granulation tissue is level with the surrounding skin
- When exudate level is less than 20 ml per day
- There is no improvement/reduction in wound size over 2 week period
- Patient is experiencing pain
- There is a change in the patient's health, home environment or Social circumstances that affects the safe and effective use of NPWT.
- If any signs of systemic infection of localised cellulitis.

On discontinuing NPWT the patients wound should be re-assessed and a new treatment objective and care plan should be devised. Advice and support should be sought from the Tissue Viability Service to help the Registered Healthcare Professional with any wound management issues.

Where applicable the Registered Healthcare Professionals must inform the Hospital Consultant when NPWT is discontinued.

NPWT dressing removal

- All patients with any wound dressing including TNP/VAC therapy should, if possible have their wounds swabbed within 24 hours of admission as per MRSA admission screening protocol

Gently remove an existing NPWT dressing according to the following procedure:

i. Raise the tubing connectors above the level of the therapy unit

ii. Close clamp on the dressing tubing

iii. Separate canister tubing and dressing tubing by disconnecting the connector

iv. Allow the therapy unit to pull the exudate in the canister tube into the canister, and then close the clamp on the canister tubing

v. Press THERAPY ON/OFF to deactivate the NPWT device

vi. Wait for 2-3 minutes to allow for foam or gauze to decompress. To remove the drape from the skin, gently stretch the drape horizontally to release adhesive from the skin

vii. Do not peel vertically. Gently remove foam or gauze from the wound

viii. If the foam or gauze has adhered to the wound base apply sterile 0.9% Sodium Chloride into the tube and leave to soak for 15-30 minutes prior to removal

ix. Discard disposables in to the Trust's yellow waste bins

Changing NPWT canisters:

Change the NPWT canisters according to the following procedure:

i. Raise the tubing connectors above the level of the therapy unit

ii. Close clamp on the dressing tubing.

iii. Separate canister tubing and dressing tubing by disconnecting the connector.

iv. Allow the therapy unit to pull the exudate in the canister tube into the canister, and then close the clamp on the canister tubing.

v. Release canister by either pushing the white arrow button to release or depressing lever on the side of the canister to pull it off.

vi. Record exudate levels, type and colour on assessment chart.

vii. Dispose of as clinical waste into the Trust yellow waste bins.

viii. Ensure the gel in the new canister is lying flat.

ix. Connect new canister to tubing.

x. Place canister into pump until it clicks.

Vac Therapy in the Open Abdomen: ABThera™

VAC therapy can be applied to patients who have open abdominal cavities where the viscera is exposed. It is efficacious for the reduction of exudate from the open abdomen, early fascial closure, shorter length of hospital stay, lower mortality and improvements in patient's quality of life. NICE (2013)

Caution is required in patients, who are at high risk of fistulation or of further bowel injury.

The decision to use VAC therapy in this clinical situation should be made by the Consultant in charge. The abdominal VAC dressing should be applied by staff that have been trained in this specific technique. In a Sterile Theatre Setting.
The procedure for obtaining and returning the NPWT pumps: (see Appendix 1, 2, 3, 4)

Discharging into the Worcestershire Community on NPWT:

- As soon as the patient is medically fit for discharge the discharge process should begin, funding should be applied for. **The patient must not be discharged until funding has been agreed and District nurses are aware.**
- All referrals for NPWT treatment funding need to be completed prior to discharge (see Appendix 12)
- The Registered Healthcare Professional responsible for discharge will ensure that there is sufficient stock available on discharge: 1 dressing and canister change. Herefordshire &Worcestershire Health and Care NHS Trust.

The Trust will be charged for the rental of a NPWT device from the supplier until the supplier is informed that the patient no longer requires it. Therefore it is important to deactivate and return the NPWT device to the supplier promptly after use. (Appendix1, 2)

V.A.C. Pumps must not leave the hospital site unless the process outlined in Appendix 1&2 has been followed.

Patients who live in surrounding / other Local Authorities, it is imperative that the Tissue Viability Team for that area is contacted to establish if VAC therapy is supported and funded in that community services, please contact Tissue Viability Team ,in order for them to liaise with other Trust Provider Services.

6 Implementation

6.1 Plan for implementation

- Tissue Viability Wound Assessment and Management Study Day including Vac Training and competence.
- Tissue Viability Website Resource.

6.2 Dissemination

This document will be available on intranet and replaces the previous versions of this document.

6.3 Training and awareness

Training is provided via workshops for staff using a competency framework. Support is also available in the clinical area on a one to one basis from the Tissue Viability team. NPWT is a non-invasive active wound healing therapy. Due to its specific mode of action staff require training and competence.

7 Monitoring and compliance:

- TissueViability Team will audit Datix Incidents arising from the clinicians not following guidance. To ascertain lessons learnt and to disseminate via TV newsletter or via Trust Lesson of the week.

The NHSLA requirements are –

Organisations should measure, monitor and evaluate compliance with the minimum requirements within the NHSLA Risk Management Standards. This should include the use of audits and data related to the minimum requirements. The organisation should define the frequency and detail of the measurement, monitoring and evaluation processes.

Monitoring demonstrates whether or not the process for managing risk, as described in the approved documentation, is working across the entire organisation. Where failings have been identified, action plans must have been drawn up and changes made to reduce the risks. Monitoring is normally proactive - designed to highlight issues before an incident occurs - and should consider both positive and negative aspects of a process.

The table below should help to detail the 'Who, What, Where and How' for the monitoring of this Policy.

Page/ Section of Key Document	Key control:	Checks to be carried out to confirm compliance with the Policy:	How often the check will be carried out:	Responsible for carrying out the check:	Results of check reported to: *(Responsible for also ensuring actions are developed to address any areas of non-compliance)*	Frequency of reporting:
	WHAT?	**HOW?**	**WHEN?**	**WHO?**	**WHERE?**	**WHEN?**
	Staff competency on VAC application and management	*Record staff attendance to VAC training / wound assessment days. *Bespoke training at ward level re updates/new training for application	Ward training record check every : every 12 months	Ward manager	Ward managers , matrons , Divisional directors of Nursing ,	Every 12 months .

8 Policy Review

Every 2 years by Tissue Viability Lead Nurse

9 References:

Abbots, J. (2010) Patients Views on Topical Negative Pressure: 'Effective But Smelly'. *British Journal of Nursing,* 19 (20), 37-41.

Banwell, P. (2007) *V.A.C. therapy clinical guidelines: a reference source for clinicians*. London, KCI Medical Ltd.

Banwell PE (1999) Topical Negative Pressure Therapy in wound care. Journal of Wound Care Vol 8 No 2. Page 79 – 84

Beldon, P. (2005) Topical negative pressure dressings and vacuum assisted closure. *Wound Essentials,* 1, 110–14.

Benbow, M. (2008) Modern Wound Therapies. *Journal Of Community Nursing,* 22 (2).

Bondokji, S. et al. (2011) Clinical Efficacy Of A New Variant Of Foam Based NWPT System. *Journal Of Wound Care*, 20 (2), 62-67.
Department of Health (2005) *Mental Health Capacity Act*. London, Department of Health.

European Pressure Ulcer Advisory Panel and National Pressure Ulcer Advisory Panel (2009) *Treatment of pressure ulcers: Quick Reference Guide*. Washington DC, National Pressure Ulcer Advisory Panel.

European Wound Management Association (2007) *Topical Negative pressure in wound management*. [Online] Available from: www.ewma.org [Accessed 31st May 2013].

FDA (2011) *FDA Safety Communication: UPDATE on Serious Complications Associated with Negative Pressure Wound Therapy Systems*. [Online]
Available from:
http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm244211.htm

Malahias, M. Hindocha, S. Saedi, F. McArthur, P. (2012) Topical Negative Pressure Therapy: Current Concepts And Practice. *Journal Of Perioperative Practice,* 22 (10), 328-332.
Milne, J. (2013) Effective Use Of Negative Pressure Wound Therapy. *Practice Nursing*, 24 (1), 14-19.

NICE (2005) Pressure Ulcers: *The Management of Pressure Ulcers in Primary and Secondary Care*. London, NICE.

NICE (2013) Negative pressure wound therapy for the open abdomen. NICE interventional procedure guidance 467. National Institute for Health and Care Excellence. London.
https://www.nice.org.uk/guidance/IPG467 Negative pressure wound therapy for the open abdomen

The V.A.C. Veraflo Therapy system for infected wounds. Medtech innovation briefing [MIB189]Published date: 02 September 2019.
https://www.nice.org.uk/advice/mib189/chapter/The-technology

Plikaitis CM and Molnar JA. (2006) Sub atmospheric pressure wound therapy and the vacuum assisted closure device – basic science and current clinical successes. Expert Review of Medical Devices. 3 (2) Page 175 – 184

Ritchie, K. Abbotts, J. Downie, S. Harbour, J. Kelly, J. Riches, E. Wilson, L. (2010) *HTA Programme: Health Technology Assessment Report 12: Topical negative pressure therapy for wounds*. Edinburgh, NHS Quality Improvement Scotland.
Stephen-Haynes, J., Woodrow, T., Wharton, S. (2011a) V.A.C Therapy. *Wounds UK,* 7 (4), 1-4.

Thompson, G. (2008) An Overview Of Negative Pressure Wound Therapy (NPWT). *Wound Care,* 23-30.

Wounds UK (2008) *Best Practice Statement: Gauze-based Negative Pressure Wound Therapy.* Aberdeen, Wounds UK.
https://www.woundsresearch.com/article/management-high-energy-soft-tissue-injury-lower-extremity-using-negative-pressure-wound

Vowden K, Teot L, Vowden P. (2007) Selecting Topical Negative Pressure Therapy in practice. In European Wound Management Association EWMA (2007) Topical Negative Pressure in Wound Management.

10 Background

10.1 Equality requirements

Supporting Document 1

10.2 Financial risk assessment

No Financial risks.

10.3 Consultation

Contribution List

This key document has been circulated to the following individuals for consultation;

Designation

This key document has been circulated to the chair(s) of the following committee's / groups for comments;

Committee

10.4 Approval Process

This policy will be approved via Clinical Governance Group.

10.5 Version Control

Date	Amendment	By:

Appendices

Appendix 1. WRH Site NPWT Process

Appendix 1
WAHT-NUR-091.pdf

Appendix 2. Alex Site NPWT Process

Appendix 2
WAHT-NUR-091.pdf

Appendix 3. V.A.C® Unit Contents

Appendix 3
WAHT-NUR-091.pdf

Appendix 4. WRH site Engie returns note

Appendix 4
WAHT-NUR-091.pdf

Appendix 5. V.A.C® therapy Guidelines

Appendix 5
WAHT-NUR-091.pdf

Appendix 6. Dressing Application Guide

Appendix 6
WAHT-NUR-091.pdf

Appendix 7. V.A.C ® Pressure Setting re Dressing Selection

Appendix 7
WAHT-NUR-091.pdf

Appendix 8 V.A.C .ULTA® troubleshooting guide

Appendix 8
WAHT-NUR-091.pdf

Appendix 9. ActiV.A.C® troubleshooting guide

Appendix 9
WAHT-NUR-091.pdf

Appendix 10. V.A.C® Competency

Appendix 10
WAHT-NUR-091.pdf

Appendix 11. Patient Information Leaflet

Appendix 11
WAHT-NUR-091.pdf

Appendix 12. Community Referral form

Appendix 12
WAHT-NUR-091.pdf

Appendix 13. Ward Product List

Appendix 13
WAHT-NUR-091.pdf

Appendix 14. Exhaustive Product List

Appendix 14
WAHT-NUR-091.pdf

Supporting Document 1 - Equality Impact Assessment Tool
To be completed by the key document author and attached to key document when submitted to the appropriate committee for consideration and approval.

NHS Worcestershire Acute Hospitals NHS Trust

Herefordshire & Worcestershire STP - Equality Impact Assessment (EIA) Form
Please read EIA guidelines when completing this form

Section 1 - Name of Organisation (please tick)

Herefordshire & Worcestershire STP		Herefordshire Council		Herefordshire CCG	
Worcestershire Acute Hospitals NHS Trust	X	Worcestershire County Council		Worcestershire CCGs	
Worcestershire Health and Care NHS Trust		Wye Valley NHS Trust		Other (please state)	

Name of Lead for Activity	**Claire Hughes**

Details of individuals completing this assessment	**Name**	**Job title**	**e-mail contact**
	Claire Hughes	**Lead TV Nurse**	**Claire.hughes9@nhs.net**
Date assessment completed	**08.04.21**		

Section 2

Activity being assessed (e.g. policy/procedure, document, service redesign, policy, strategy etc.)	**Title:** **Guideline for the Use of Negative Pressure Wound Therapy (NPWT)**			
What is the aim, purpose and/or intended outcomes of this Activity?	To maintain staff competency when assessing & applying NPWT .			
Who will be affected by the development & implementation of this activity?	X X ❑	Service User Patient Carers	X ❑ ❑	Staff Communities Other _____

	❑	Visitors	❑	
Is this:	❑ Review of an existing activity ❑ New activity ❑ Planning to withdraw or reduce a service, activity or presence?			
What information and evidence have you reviewed to help inform this assessment? (Please name sources, eg demographic information for patients / services / staff groups affected, complaints etc.				
Summary of engagement or consultation undertaken (e.g. who and how have you engaged with, or why do you believe this is not required)				
Summary of relevant findings				

Section 3

Please consider the potential impact of this activity (during development & implementation) on each of the equality groups outlined below. **Please tick one or more impact box below for each Equality Group and explain your rationale**. Please note it is possible for the potential impact to be both positive and negative within the same equality group and this should be recorded. Remember to consider the impact on e.g. staff, public, patients, carers etc. in these equality groups.

Equality Group	Potential positive impact	Potential neutral impact	Potential negative impact	Please explain your reasons for any potential positive, neutral or negative impact identified
Age		X		
Disability		X		
Gender Reassignment		X		
Marriage & Civil Partnerships		X		
Pregnancy & Maternity		X		
Race including Traveling Communities		X		
Religion & Belief		X		
Sex		X		

Equality Group	Potential positive impact	Potential neutral impact	Potential negative impact	Please explain your reasons for any potential positive, neutral or negative impact identified
Sexual Orientation		X		
Other Vulnerable and Disadvantaged Groups (e.g. carers; care leavers; homeless; Social/Economic deprivation, travelling communities etc.)				
Health Inequalities (any preventable, unfair & unjust differences in health status between groups, populations or individuals that arise from the unequal distribution of social, environmental & economic conditions within societies)		X		

Section 4

What actions will you take to mitigate any potential negative impacts?	Risk identified	Actions required to reduce / eliminate negative impact	Who will lead on the action?	Timeframe
	Staff Training	*Regularly updated staff competencies*	**Ward managers**	**Ongoing**
How will you monitor these actions?				
When will you review this EIA? (e.g in a service redesign, this EIA should be revisited regularly throughout the design & implementation)				

Section 5 - Please read and agree to the following Equality Statement

1. Equality Statement

1.1. All public bodies have a statutory duty under the Equality Act 2010 to set out arrangements to assess and consult on how their policies and functions impact on the 9 protected characteristics: Age; Disability; Gender Reassignment; Marriage & Civil Partnership; Pregnancy & Maternity; Race; Religion & Belief; Sex; Sexual Orientation

1.2. Our Organisations will challenge discrimination, promote equality, respect human rights, and aims to design and implement services, policies and measures that meet the diverse needs of our service, and population, ensuring that none are placed at a disadvantage over others.
1.3. All staff are expected to deliver services and provide services and care in a manner which respects the individuality of service users, patients, carer's etc, and as such treat them and members of the workforce respectfully, paying due regard to the 9 protected characteristics.

Signature of person completing EIA	
Date signed	
Comments:	
Signature of person the Leader Person for this activity	
Date signed	
Comments:	

Supporting Document 2 – Financial Impact Assessment

To be completed by the key document author and attached to key document when submitted to the appropriate committee for consideration and approval.

	Title of document:	Yes/No
1.	Does the implementation of this document require any additional Capital resources	YES
2.	Does the implementation of this document require additional revenue	YES
3.	Does the implementation of this document require additional manpower	NO
4.	Does the implementation of this document release any manpower costs through a change in practice	NO
5.	Are there additional staff training costs associated with implementing this document which cannot be delivered through current training programmes or allocated training times for staff	NO
	Other comments: *NPWT yearly budget is held within the Tissue Viability Budget *This includes Daily rental costs of units *NPWT unit process in place , available on Trust Tissue Viability Intranet to Access	

If the response to any of the above is yes, please complete a business case and which is signed by your Finance Manager and Directorate Manager for consideration by the Accountable Director before progressing to the relevant committee for approval